HC Wainwright Forecasts Increased Earnings for MacroGenics

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for MacroGenics to $(0.63) from $(3.01), and also lifted its FY2026 outlook to $(1.82) per share.
• Other analysts have been mixed but generally more optimistic recently, with Barclays and B. Riley Financial both raising price targets and B. Riley upgrading the stock to buy. The consensus rating remains Hold, with an average price target of $5.40.
• MacroGenics recently reported better-than-expected Q4 results, posting EPS of $(0.22) versus an estimated $(0.42) and revenue of $41.23 million, well above the $27.81 million consensus.

MacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for MacroGenics in a report released on Thursday, May 7th. HC Wainwright analyst R. Burns now expects that the biopharmaceutical company will earn ($0.63) per share for the quarter, up from their prior forecast of ($3.01). The consensus estimate for MacroGenics' current full-year earnings is ($1.32) per share. HC Wainwright also issued estimates for MacroGenics' Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.71) EPS and FY2026 earnings at ($1.82) EPS.

A number of other equities analysts have also recently issued reports on the company. Barclays increased their price target on MacroGenics from $4.00 to $6.00 and gave the stock an "overweight" rating in a report on Monday, April 20th. Wall Street Zen upgraded MacroGenics from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. Citigroup restated a "market perform" rating on shares of MacroGenics in a report on Tuesday, February 24th. Finally, B. Riley Financial upgraded MacroGenics from a "neutral" rating to a "buy" rating and increased their price target for the stock from $3.00 to $9.00 in a report on Friday, April 10th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, MacroGenics currently has an average rating of "Hold" and an average price target of $5.40.

MacroGenics Stock Performance

Shares of MacroGenics stock opened at $3.00 on Monday. The business has a 50-day moving average price of $2.97 and a two-hundred day moving average price of $2.10. MacroGenics has a 1-year low of $1.18 and a 1-year high of $3.88. The company has a market cap of $190.68 million, a P/E ratio of -2.56 and a beta of 1.08.

MacroGenics (NASDAQ:MGNX - Get Free Report) last issued its quarterly earnings results on Monday, March 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.20. MacroGenics had a negative return on equity of 120.19% and a negative net margin of 49.91%.The firm had revenue of $41.23 million during the quarter, compared to the consensus estimate of $27.81 million.

Hedge Funds Weigh In On MacroGenics

Institutional investors and hedge funds have recently made changes to their positions in the stock. R Squared Ltd bought a new position in shares of MacroGenics during the 4th quarter worth about $26,000. SG Americas Securities LLC lifted its position in MacroGenics by 55.9% in the 3rd quarter. SG Americas Securities LLC now owns 17,179 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 6,161 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in MacroGenics in the 3rd quarter valued at about $38,000. Engineers Gate Manager LP bought a new position in MacroGenics in the 2nd quarter valued at about $28,000. Finally, Walleye Capital LLC bought a new position in MacroGenics in the 2nd quarter valued at about $30,000. Institutional investors own 96.89% of the company's stock.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics' research platform are its ADAPTIR and Trident bispecific antibody technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.